Orphan Drugs - Global Strategic Business Report

The global market for Orphan Drugs is estimated at US$361.7 Billion in 2023 and is projected to reach US$959.0 Billion by 2030, growing at a CAGR of 14.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Looking to the future, the realm of orphan drugs is set to expand with the growing integration of advanced technologies and shifting regulatory landscapes. Advances in genetic research and biotechnology have dramatically enhanced the identification and understanding of rare diseases at a molecular level, facilitating the development of targeted treatments. The movement towards personalized medicine continues to push the boundaries of precision therapies, tailored to individual genetic profiles, significantly improving patient outcomes. Furthermore, regulatory incentives and fast-track approval processes provided by entities such as the FDA and EMA are crucial in encouraging the development of orphan drugs. Collaborative research initiatives and innovative funding models are also pivotal, reducing the financial burden and fostering faster drug development. As awareness and advocacy grow, so does the support for addressing the unique challenges posed by rare diseases, thereby driving the demand for orphan drugs and underlining the importance of continued innovation and support in this crucial healthcare sector.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Biologics Drug Type segment, which is expected to reach US$612.3 Billion by 2030 with a CAGR of a 15.5%. The Non-Biologics Drug Type segment is also set to grow at 14.0% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $99.2 Billion in 2023, and China, forecasted to grow at an impressive 14.1% CAGR to reach $145.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Orphan Drugs Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Orphan Drugs Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Orphan Drugs Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as AbbVie Inc., Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals Inc., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 18 Featured):

AbbVie Inc.
Actelion Pharmaceuticals Ltd.
Alexion Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca Plc.
Bayer AG
Biogen Inc.
BioMarin Pharmaceutical Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp.
CEL-SCI Corporation
Concordia International Corp.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genzyme Corp.,
Johnson & Johnson
Merck & Co. Inc.
Merck Serono SA
Novartis AG
Pfizer Inc.
Recordati S.p.A.
Sanofi SA
Shire Plc.
Vertex Pharmaceuticals

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Orphan Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Increasing Prevalence of Rare Diseases
Growth of Biopharmaceutical Industry
Advancements in Genetic and Molecular Research
Rising Adoption of Personalized Medicine
Impact of COVID-19 Pandemic on Orphan Drug Development
Government Regulations and Incentives for Orphan Drugs
Expansion of Orphan Drug Applications in Various Therapeutic Areas
Development of Novel Drug Delivery Systems for Orphan Drugs
Consumer Preferences for Innovative and Effective Treatments
Role of Orphan Drugs in Enhancing Patient Outcomes and Quality of Life
Market Penetration of Orphan Drugs in Developing Regions
Influence of Technological Innovations on Orphan Drug Development
Growth of Orphan Drugs in Oncology and Rare Genetic Disorders
Emerging Markets and Growth Opportunities in Developing Regions
Future Trends and Innovations in Orphan Drug Research and Development

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Orphan Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 17: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 18: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 19: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 20: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 21: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: World 16-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 23: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 24: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 26: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 27: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: World 16-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 29: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 30: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 32: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 33: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 35: USA Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: USA 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 38: USA Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: USA 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

CANADA

Table 41: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: Canada 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 44: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: Canada 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

JAPAN

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 47: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 48: Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: Japan 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 50: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: Japan 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

CHINA

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 53: China Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 54: China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 55: China 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 56: China Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 57: China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 58: China 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

EUROPE

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 59: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 60: Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 61: Europe 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 62: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 63: Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 64: Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 65: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 66: Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 67: Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

FRANCE

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 68: France Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 69: France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 70: France 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 71: France Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 72: France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 73: France 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

GERMANY

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 74: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 75: Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 76: Germany 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 77: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 78: Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 79: Germany 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

ITALY

Table 80: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 81: Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 82: Italy 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 83: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 84: Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 85: Italy 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

UNITED KINGDOM

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 86: UK Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 87: UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 88: UK 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 89: UK Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 90: UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 91: UK 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 92: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 93: Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 94: Rest of Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 95: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 96: Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 97: Rest of Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 99: Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 100: Asia-Pacific 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 102: Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 103: Asia-Pacific 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

REST OF WORLD

Table 104: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 105: Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 106: Rest of World 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
Table 107: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 108: Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 109: Rest of World 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie Inc.
Actelion Pharmaceuticals Ltd.
Alexion Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca Plc.
Bayer AG
Biogen Inc.
BioMarin Pharmaceutical Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp.
CEL-SCI Corporation
Concordia International Corp.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genzyme Corp.,
Johnson & Johnson
Merck & Co. Inc.
Merck Serono SA
Novartis AG
Pfizer Inc.
Recordati S.p.A.
Sanofi SA
Shire Plc.
Vertex Pharmaceuticals

Table Information

Report Attribute	Details
No. of Pages	261
Published	September 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 361.7 Billion
Forecasted Market Value ( USD ) by 2030	$ 959 Billion
Compound Annual Growth Rate	14.9%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5176EUR$5,600USD£4,318GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9834EUR$10,640USD£8,204GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15527EUR$16,800USD£12,954GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 18 Featured):

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Global Orphan Drugs Market Analysis & Forecast 2024-2034: Market By Drug Type; By Therapy; By Distribution Channel; and By Region

Global Orphan Drugs Market by Disease Type (Gastrointestinal, Hematology, Infectious Diseases), Product Type (Biologic, Non-Biologic), Distribution Channel - Forecast 2024-2030

Orphan Drugs Global Market Report 2024

Global Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2024-2032

Global Orphan Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029